MobieTrain services frontline, and often deskless, workers.
The round was led by British-Belgian venture fund Force Over Mass Capital; existing investors, LRM and Concentra, also participated in the Series A.
As the name suggests, MobieTrain is a digital learning platform. However, it is specifically optimized for and aimed at frontline workers, who often struggle to keep their knowledge and skills up-to-date due to the busy and deskless nature of their work.
MobieTrain’s so-called microlearning technology employs gamification to make learning bite-sized and personalized so it can be picked up whenever suits the frontline staff.
The company plans to use the funding to further develop its learning platform, as well as grow its teams in Belgium, the Netherlands, and Portugal from 25 to 40 employees.
MobieTrain CEO and founder Guy Van Neck commented: We’re proud that we have large investors backing our strong ambitions for growth.
“Our mission of making learning accessible to all employees and thereby adding to their development has only just begun.”
The company’s CTO Willi Van Boven added: “By adding new gamified elements, we help elevate employees’ intrinsic motivation.
“Furthermore, it’s important to offer the right educational content to the right person at the right time. To do so, algorithms and machine learning play a crucial role. Such aspects have our full attention in the upcoming months.”
This investment comes on the back of a very strong year of growth for MobieTrain. The company says its revenue has grown by 400% and it was able to double its client numbers in 2020.
MobieTrain now provides learning to employees at companies like Diesel, Timberland, Emirates Post, and Deloitte, as well as public sector organizations like the Dutch police and Belgian government departments.
Allie started her career as a business journalist writing about innovation in the pharma and medtech industries. She learned how crucial technology was to these medical breakthroughs and therefore became keen to further explore how it could also disrupt not just our health, and the way we live, but the way we work. Allie’s work has been featured in Pharma Tech Focus, Medical Technology Magazine, Verdict.co.uk, and Glass Magazine.